SLNP-based CDK4- targeted nanotherapy against glioblastoma

IntroductionGlioblastoma is a grade IV solid brain tumor and has a 15-month survival rate even after treatment. Glioblastoma development is heavily influenced by retinoblastoma protein (pRB) pathway changes. The blood–brain barrier, drug resistance, and severe toxicity of Temozolamide are key obstac...

Full description

Saved in:

Bibliographic Details
Main Authors:	Uzma Ghani, Fareeha Khalid Ghori, Muhammad Usman Qamar, Hina Khan, Basit Azad, Sabahat Habib, Saira Justin, Ishaq N. Khan, Tawaf Ali Shah, Gamal A. Shazly, Mohammed Bourhia, Fouzia Perveen, Aneela Javed
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	blood brain barrier glioblastoma silymarin solid lipid nanoparticles temozolamide
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1455816/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

SLNP-based CDK4- targeted nanotherapy against glioblastoma

Similar Items